Bausch + Lomb (BLCO) Expected to Announce Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is projected to announce its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $1.2146 billion for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The company’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.25 EPS. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Price Performance

NYSE BLCO opened at $15.84 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.55 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $5.65 billion, a PE ratio of -15.53, a price-to-earnings-growth ratio of 0.66 and a beta of 0.65. The company has a 50 day moving average price of $16.79 and a two-hundred day moving average price of $16.50. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $18.92.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BLCO shares. Citigroup raised their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Evercore set a $18.00 price objective on shares of Bausch + Lomb and gave the stock an “in-line” rating in a report on Monday, January 5th. Wells Fargo & Company raised their target price on Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bausch + Lomb in a research report on Monday, April 20th. Finally, HC Wainwright upped their price target on Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bausch + Lomb has a consensus rating of “Hold” and a consensus price target of $18.25.

Insider Buying and Selling

In other news, EVP A Robert D. Bailey bought 14,600 shares of the business’s stock in a transaction on Friday, March 6th. The stock was purchased at an average price of $17.15 per share, with a total value of $250,390.00. Following the transaction, the executive vice president directly owned 231,890 shares in the company, valued at approximately $3,976,913.50. The trade was a 6.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sam Eldessouky purchased 4,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $17.13 per share, with a total value of $68,520.00. Following the completion of the acquisition, the chief financial officer directly owned 403,130 shares of the company’s stock, valued at approximately $6,905,616.90. This trade represents a 1.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 33,300 shares of company stock valued at $570,868. Company insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

Several large investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its stake in Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after purchasing an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the period. Wells Fargo & Company MN increased its position in Bausch + Lomb by 31.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the period. Focus Partners Wealth acquired a new position in shares of Bausch + Lomb during the third quarter worth approximately $170,000. Finally, Invesco Ltd. acquired a new position in shares of Bausch + Lomb during the fourth quarter worth approximately $178,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.